Recent Security Class Actions

Aldeyra Therapeutics Inc. Common Stock (NASDAQ: ALDX)

Company Name:Aldeyra Therapeutics Inc. Common Stock
Stock Symbol:NASDAQ: ALDX
Class Period Start:01/07/2021
Class Period End (inclusive):10/16/2023
Filing Deadline:09/29/2023

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) the ADX-2191 new drug application (“NDA”) did not include adequate and well-controlled investigations and thus failed to show substantial evidence of ADX-2191's effectiveness; (ii) as a result, the FDA was unlikely to approve the ADX-2191 NDA in its current form; (iii) accordingly, the Company had overstated ADX-2191's clinical and/or commercial prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.